Real-time, high-resolution imaging of tumor cells in genetically engineered and orthotopic models of thyroid cancer.

Abstract:

:Genetically engineered and orthotopic xenograft mouse models have been instrumental for increasing our understanding of thyroid cancer progression and for the development of novel therapeutic approaches in a setting that is more physiologically relevant than the classical subcutaneous flank implants. However, the anatomical location of the thyroid gland precludes a non-invasive analysis at the cellular level of the interactions between tumor cells and the surrounding microenvironment and does not allow a real-time evaluation of the response of tumor cells to drug treatments. As a consequence, such studies have generally only relied on endpoint approaches, limiting the amount and depth of the information that could be gathered. Here we describe the development of an innovative approach to imaging specific aspects of thyroid cancer biology, based on the implantation of a permanent, minimally invasive optical window that allows high-resolution, multi-day, intravital imaging of the behavior and cellular dynamics of thyroid tumors in the mouse. We show that this technology allows visualization of fluorescently tagged tumor cells both in immunocompetent, genetically engineered mouse models of anaplastic thyroid cancer (ATC) and in immunocompromised mice carrying orthotopic implanted human or mouse ATC cells. Furthermore, the use of recipient mice in which endothelial cells and macrophages are fluorescently labeled allows the detection of the spatial and functional relationship between tumor cells and their microenvironment. Finally, we show that ATC cells expressing a fluorescent biosensor for caspase 3 activity can be effectively utilized to evaluate, in real-time, the efficacy and kinetics of action of novel small molecule therapeutics. This novel approach to intravital imaging of thyroid cancer represents a platform that will allow, for the first time, the longitudinal, in situ analysis of tumor cell responses to therapy and of their interaction with the microenvironment.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Shanja-Grabarz X,Coste A,Entenberg D,Di Cristofano A

doi

10.1530/ERC-20-0295

subject

Has Abstract

pub_date

2020-10-01 00:00:00

pages

529-539

issue

10

eissn

1351-0088

issn

1479-6821

pii

ERC-20-0295

journal_volume

27

pub_type

杂志文章
  • Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.

    abstract::Most endocrine therapies for breast cancer inhibit tumor growth by depriving the cell of estrogen or by blocking its receptor. However, some drugs, such as tamoxifen, can bind to the estrogen receptor (ER) and have both estrogenic and antiestrogenic effects, depending on the tissue, cell, or promoter context. These mi...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060271

    authors: Osborne CK

    更新日期:1999-06-01 00:00:00

  • Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma.

    abstract::Numerous epidemiological observations point to sex differences in lung cancer etiology and progression. The present study was aimed at understanding the bases of these sex differences. To test the effect of estradiol on tumor progression, we used a mouse model based on conditional Kras expression and concurrent deleti...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0002

    authors: Hammoud Z,Tan B,Badve S,Bigsby RM

    更新日期:2008-06-01 00:00:00

  • Modifying impact of RET gene haplotypes on medullary thyroid carcinoma clinical course.

    abstract::The clinical course of medullary thyroid carcinoma (MTC) associated with the MEN2A syndrome as well as of sporadic MTC shows considerable heterogeneity. The disease picture varies not only between the same RET proto-oncogene mutation carriers but also among sporadic MTC patients with no RET germinal mutations, which s...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0452

    authors: Kaczmarek-Ryś M,Ziemnicka K,Pławski A,Budny B,Michalak M,Hryhorowicz S,Hoppe-Gołębiewska J,Boruń P,Gołąb M,Czetwertyńska M,Sromek M,Szalata M,Ruchała M,Słomski R

    更新日期:2018-04-01 00:00:00

  • Targeting muscle signaling pathways to minimize adverse effects of androgen deprivation.

    abstract::Androgen deprivation therapy (ADT) is a highly effective treatment used in ∼30% of men with prostate cancer. Adverse effects of ADT on muscle are significant with consistent losses in muscle mass. However, effects of ADT on muscle strength and physical function, of most relevance to the patient, are less well understo...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0232

    authors: de Rooy C,Grossmann M,Zajac JD,Cheung AS

    更新日期:2016-01-01 00:00:00

  • Risks of breast, endometrial, and ovarian cancers after twin births.

    abstract::The concentrations of endogenous hormones differ between women with twin and singleton births, with a possible influence on the risk of cancer. We used the nationwide Swedish Family-Cancer Database, including 30,409 women with a twin birth, to examine the subsequent risks of breast, endometrial, and ovarian cancers. R...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-07-0088

    authors: Ji J,Försti A,Sundquist J,Hemminki K

    更新日期:2007-09-01 00:00:00

  • YAP regulates cell proliferation, migration, and steroidogenesis in adult granulosa cell tumors.

    abstract::The Hippo signaling pathway has been implicated as a conserved regulator of organ size in both Drosophila and mammals. Yes-associated protein (YAP), the central component of the Hippo signaling cascade, functions as an oncogene in several malignancies. Ovarian granulosa cell tumors (GCT) are characterized by enlargeme...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-13-0339

    authors: Fu D,Lv X,Hua G,He C,Dong J,Lele SM,Li DW,Zhai Q,Davis JS,Wang C

    更新日期:2014-03-04 00:00:00

  • Genomic classification of benign adrenocortical lesions.

    abstract::Benign adrenal tumors cover a spectrum of lesions with distinct morphology and steroid secretion. Current classification is empirical. Beyond a few driver mutations, pathophysiology is not well understood. Here, a pangenomic characterization of benign adrenocortical tumors is proposed, aiming at unbiased classificatio...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-20-0128

    authors: Faillot S,Foulonneau T,Néou M,Espiard S,Garinet S,Vaczlavik A,Jouinot A,Rondof W,Septier A,Drougat L,Hécale-Perlemoine K,Ragazzon B,Rizk-Rabin M,Sibony M,Bonnet-Serrano F,Guibourdenche J,Libé R,Groussin L,Dousset B,

    更新日期:2021-01-01 00:00:00

  • Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas.

    abstract::The prognosis remains ill-defined in patients with liver metastases of well-differentiated (WD) digestive endocrine carcinomas (DEC) with high Ki-67 index. The objectives of this study were to determine whether Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in pa...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0319

    authors: Hentic O,Couvelard A,Rebours V,Zappa M,Dokmak S,Hammel P,Maire F,O'Toole D,Lévy P,Sauvanet A,Ruszniewski P

    更新日期:2010-12-13 00:00:00

  • Annual fasting plasma glucose variation increases risk of cancer incidence and mortality in patients with type 2 diabetes: the Taichung Diabetes Study.

    abstract::The study aims to examine whether the annual variations in fasting plasma glucose (FPG) measurements, represented by the coefficient of variation (CV), predict cancer incidence and mortality in the subsequent years independent of traditional risk factors of type 2 diabetic patients. A computerized database of patients...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-12-0038

    authors: Lin CC,Li CI,Liu CS,Lin WY,Chen CC,Yang SY,Lee CC,Li TC

    更新日期:2012-07-18 00:00:00

  • Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival.

    abstract::Obesity increases both the risk and mortality associated with many types of cancer including that of the breast. In mice, obesity increases both incidence of spontaneous tumors and burden of transplanted tumors. Our findings identify leptin, an adipose secreted cytokine, in promoting increased mammary tumor burden in ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0102

    authors: Zheng Q,Dunlap SM,Zhu J,Downs-Kelly E,Rich J,Hursting SD,Berger NA,Reizes O

    更新日期:2011-07-11 00:00:00

  • The optimal imaging of adrenal tumours: a comparison of different methods.

    abstract::Computed tomography (CT; unenhanced, followed by contrast-enhanced examinations) is the cornerstone of imaging of adrenal tumours. Attenuation values of <10 Hounsfield units on an unenhanced CT are practically diagnostic for adenomas. When lesions cannot be characterised adequately with CT, magnetic resonance imaging ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/ERC-07-0045

    authors: Ilias I,Sahdev A,Reznek RH,Grossman AB,Pacak K

    更新日期:2007-09-01 00:00:00

  • Factors regulating the growth of metastatic cancer in bone.

    abstract::Metastatic tumor cells can interfere directly with the function of bone cells involved in normal bone remodeling or indirectly by influencing the behavior of hematopoietic, stromal and other cells in bone marrow that interact with bone cells. Recent studies of metastatic cancer have revealed that tumor cells interact ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060333

    authors: Boyce BF,Yoneda T,Guise TA

    更新日期:1999-09-01 00:00:00

  • Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia.

    abstract::Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized in man by parathyroid, pancreatic, pituitary and adrenal tumours. The MEN1 gene encodes a 610-amino acid protein (menin) which is a tumour suppressor. To investigate the in vivo role of menin, we developed a mouse model, by dele...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0082

    authors: Harding B,Lemos MC,Reed AA,Walls GV,Jeyabalan J,Bowl MR,Tateossian H,Sullivan N,Hough T,Fraser WD,Ansorge O,Cheeseman MT,Thakker RV

    更新日期:2009-12-01 00:00:00

  • A new appraisal of iodine refractory thyroid cancer.

    abstract::Thyroid cancer incidence is increasing all over the world - mostly due to an increase in the detection of small tumors that were previously undetected. A small percentage of these tumors lose the ability to uptake and/or to respond to radioiodine (RAI) therapy, especially in metastatic patients. There are several new ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0300

    authors: Vaisman F,Carvalho DP,Vaisman M

    更新日期:2015-12-01 00:00:00

  • Autophagy in endocrine tumors.

    abstract::Autophagy is an important intracellular process involving the degradation of cytoplasmic components. It is involved in both physiological and pathological conditions, including cancer. The role of autophagy in cancer is described as a 'double-edged sword,' a term that reflects its known participation in tumor suppress...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0042

    authors: Weckman A,Rotondo F,Di Ieva A,Syro LV,Butz H,Cusimano MD,Kovacs K

    更新日期:2015-08-01 00:00:00

  • Thyrotoxicosis with concomitant thyroid cancer.

    abstract::Thyrotoxicosis with concomitant thyroid cancer is rare and poorly recognized, which may result in delayed diagnosis, inappropriate treatment and even poor prognosis. To provide a comprehensive guidance for clinicians, the etiology, pathogenesis, diagnosis and treatment of this challenging setting were systematically r...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0129

    authors: Fu H,Cheng L,Jin Y,Chen L

    更新日期:2019-07-01 00:00:00

  • Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.

    abstract::The central involvement of estrogen in the development of the mammary gland and in the genesis of breast cancer has lent impetus to studies of the links between estrogen action and the cell cycle machinery. Recent studies of the estrogenic regulation of molecules with known roles in the control of G1/S phase progressi...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0100179

    authors: Doisneau-Sixou SF,Sergio CM,Carroll JS,Hui R,Musgrove EA,Sutherland RL

    更新日期:2003-06-01 00:00:00

  • Tetrac as an anti-angiogenic agent in cancer.

    abstract::The thyroid hormones T3 and T4 have emerged as pro-angiogenic hormones with important implications for cancer management. Endogenous circulating hormone levels may help stimulate cancer progression and limit the effectiveness of anticancer therapy, though clinical data remain inconclusive. The capacity of thyroid horm...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-19-0058

    authors: Schmohl KA,Nelson PJ,Spitzweg C

    更新日期:2019-06-01 00:00:00

  • Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.

    abstract::Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare neuroendocrine tumors of the adrenal glands and the sympathetic and parasympathetic paraganglia. They can occur sporadically or as a part of different hereditary tumor syndromes. About 30% of PCCs and PGLs are currently believed to be caused by germline mutat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-11-0170

    authors: Welander J,Söderkvist P,Gimm O

    更新日期:2011-12-01 00:00:00

  • Genetically defined mouse models that mimic natural aspects of human prostate cancer development.

    abstract::This review is focused on mouse models for prostate cancer that have been designed on the basis of genetic alterations that are frequently found in human prostate cancer. It begins with an analysis of the similarities and differences in the gross and microscopic anatomy of the mouse and human prostate glands, and exte...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0110225

    authors: Roy-Burman P,Wu H,Powell WC,Hagenkord J,Cohen MB

    更新日期:2004-06-01 00:00:00

  • Trp63 is regulated by STAT5 in mammary tissue and subject to differentiation in cancer.

    abstract::Transformation-related protein 63 (Trp63), the predominant member of the Trp53 family, contributes to epithelial differentiation and is expressed in breast neoplasia. Trp63 features two distinct promoters yielding specific mRNAs encoding two major TRP63 isoforms, a transactivating transcription factor and a dominant n...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0032

    authors: Assefnia S,Kang K,Groeneveld S,Yamaji D,Dabydeen S,Alamri A,Liu X,Hennighausen L,Furth PA

    更新日期:2014-05-06 00:00:00

  • Circulating microRNAs: macro-utility as markers of prostate cancer?

    abstract::The realization that microRNAs (miRNAs) are frequently deregulated in malignancy has had a major impact on cancer research. In particular, the recent finding that highly stable forms of miRNAs can be accurately measured in body fluids, including blood, has generated considerable excitement. Here, we discuss the potent...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0010

    authors: Selth LA,Tilley WD,Butler LM

    更新日期:2012-06-18 00:00:00

  • The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.

    abstract::Experimental models of neuroendocrine tumour disease are scarce, and no comprehensive characterisation of existing gastroenteropancreatic neuroendocrine tumour (GEPNET) cell lines has been reported. In this study, we aimed to define the molecular characteristics and therapeutic sensitivity of these cell lines. We ther...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0445

    authors: Hofving T,Arvidsson Y,Almobarak B,Inge L,Pfragner R,Persson M,Stenman G,Kristiansson E,Johanson V,Nilsson O

    更新日期:2018-03-01 00:00:00

  • Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.

    abstract::Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited treatment options. We explored novel treatment modalities by targeting epigenetic modifications using inhibitors of BET (e.g. BRD4) activity. We evaluated the efficacy in the treatment of ATC of a novel BET inhibitor, PLX51107 (PLX), currently in...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0107

    authors: Zhu X,Park S,Lee WK,Cheng SY

    更新日期:2019-09-01 00:00:00

  • Acquired resistance to aromatase inhibitors: where we stand!

    abstract::Aromatase inhibitors (AIs) are one of the principal therapeutic approaches for estrogen receptor-positive (ER+) breast cancer in postmenopausal women. They block estrogen biosynthesis through aromatase inhibition, thus preventing tumour progression. Besides the therapeutic success of the third-generation AIs, acquired...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-17-0425

    authors: Augusto TV,Correia-da-Silva G,Rodrigues CMP,Teixeira N,Amaral C

    更新日期:2018-05-01 00:00:00

  • The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs).

    abstract::Non-functioning pituitary adenomas, recently alternatively termed pituitary neuroendocrine tumours (NFpitNETs), are mostly benign neoplasms that are not associated with a hormonal hypersecretory syndrome. The clinical spectrum of NFpitNETs varies from completely asymptomatic to the development of panhypopituitarism an...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-20-0136

    authors: Yavropoulou MP,Tsoli M,Barkas K,Kaltsas G,Grossman A

    更新日期:2020-10-01 00:00:00

  • Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors.

    abstract::Tropomyosin receptor kinase (Trk) inhibitors are investigated as a novel targeted therapy in various cancers. We investigated the in vitro effects of the pan-Trk inhibitor GNF-5837 in human neuroendocrine tumor (NET) cells. The human neuroendocrine pancreatic BON1, bronchopulmonary NCI-H727 and ileal GOT1 cell lines w...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0201

    authors: Aristizabal Prada ET,Heinzle V,Knösel T,Nölting S,Spöttl G,Maurer J,Spitzweg C,Angele M,Schmidt N,Beuschlein F,Stalla GK,Blaser R,Kuhn KA,Auernhammer CJ

    更新日期:2018-05-01 00:00:00

  • 65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma.

    abstract::Although the authors of the present review have contributed to genetic discoveries in the field of pheochromocytoma research, we can legitimately ask whether these advances have led to improvements in the diagnosis and management of patients with pheochromocytoma. The answer to this question is an emphatic Yes! In the...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-18-0085

    authors: Neumann HP,Young WF Jr,Krauss T,Bayley JP,Schiavi F,Opocher G,Boedeker CC,Tirosh A,Castinetti F,Ruf J,Beltsevich D,Walz M,Groeben HT,von Dobschuetz E,Gimm O,Wohllk N,Pfeifer M,Lourenço DM Jr,Peczkowska M,Patocs A,

    更新日期:2018-08-01 00:00:00

  • Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.

    abstract::There are currently few successful therapies for castration-resistant prostate cancer (CRPC). CRPC is thought to result from augmented activation of the androgen/androgen receptor (AR) signaling pathway, which could be enhanced by AR cofactors. In this study, heterochromatin protein 1beta (HP1beta), but not HP1alpha o...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0321

    authors: Shiota M,Song Y,Yokomizo A,Tada Y,Kuroiwa K,Eto M,Oda Y,Inokuchi J,Uchiumi T,Fujimoto N,Seki N,Naito S

    更新日期:2010-05-18 00:00:00

  • Advances in paraganglioma-pheochromocytoma cell lines and xenografts.

    abstract::This review describes human and rodent-derived cell lines and xenografts developed over the last five decades that are suitable or potentially suitable models for paraganglioma-pheochromocytoma research. We outline the strengths and weaknesses of various models and emphasize the recurring theme that, despite the major...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-19-0434

    authors: Bayley JP,Devilee P

    更新日期:2020-12-01 00:00:00